Brimonidine
Glaucoma drop, also used for redness and rosacea.
- Starts working
- Varies
- Half-life
- —
- In use since
- 1996
- Pregnancy
- Use with caution
Overview
Brimonidine lowers eye pressure in glaucoma. Low-dose drops whiten red eyes, and a gel reduces facial redness from rosacea. Eye allergy develops in some long-term users.
Conditions it's used for
How it works
Reduces fluid production and increases drainage.
Brimonidine belongs to the Alpha-2 agonist eye drops. How Alpha-2 agonist eye drops work: reduce fluid production and increase drainage in the eye.
Uses
- Glaucoma
- Eye redness (low dose)
- Rosacea redness (gel)
Available as: eye drops, gel.
Typical dose
- Adults
- One drop two or three times a day for glaucoma.
Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.
Side effects
Common
Often mild and may settle with time
- Allergic eye redness
- Dry mouth
- Tiredness
Serious — get medical help
Uncommon, but need prompt attention
- Breathing problems and drowsiness in infants
Warnings
- Not for children under 2
Interactions
- Sedatives — more drowsiness
Pregnancy and breastfeeding
Use with caution
Limited data.
Breastfeeding advice can differ from pregnancy advice — check with a pharmacist, or the LactMed database.
Brand names
- United States
- Alphagan P, Lumify, Mirvaso
- United Kingdom
- Alphagan, Mirvaso
- India
- Alphagan, Brimocom
- Australia
- Alphagan
Examples only; many generic versions exist. The same brand name can mean different products in different countries.
Common questions
Can I use redness drops every day?
Occasional use is fine; frequent use can mask an eye problem.
Do I need a prescription for Brimonidine?
Yes — Brimonidine is prescription-only in most countries.
Can I take Brimonidine during pregnancy?
Use with caution. Limited data. Always check with a doctor or midwife.
Related medicines
Sources and official information
- MedlinePlus (US National Library of Medicine)
- DailyMed — official US labels
- NHS medicines A–Z
- WHO ATC/DDD index — S01EA05
Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.